Monoclonal antibody therapy in rheumatoid arthritis an update on recent progress

Clinical Immunotherapeutics

Volumn 6, Issue 2, 1996, Pages 143-153

  Rankin, Elizabeth C C ^a,b   Isenberg, David A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Arthur Stanley House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; INFLAMMATORY CELL; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE;

EID: 0029786538     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259511     Document Type: Article

References (41)

1. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 1368-75
2. Burmester GR, Yu DTY, Irani AM, et al. Ia+ T-cells in synovial fluid and tissue of patients with rheumatoid arthritis. Arthritis Rheum 1986; 24: 1370-6
3. Pitzalis C, Kingsley G, Murphy J, et al. Abnormal distribution of the helper-inducer and suppressor-inducer T lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol 1987; 45: 252-8
4. Pitzalis C, Kingsley GH, Covelli M, et al. Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol 1991:21:369-76
5. Nepom GT, Byers P. Seyfried C, et al. HLA genes associated with rheumatoid arthritis. Arthritis Rheum 1989; 32: 15-21
6. Calabrese LH, Wilke WS, Perkins AD, et al. Rheumatoid arthritis complicated by infection with the human immunodeficiency virus and the development of Sjogren's syndrome. Arthritis Rheum 1989; 32: 1453-7
7. Koopman WJ. The future of biologies in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1994; 23 Suppl. 2: 50-8
8. Zhang J, Weichman BM, Lewis AJ. Role of animal models in the study of rheumatoid arthritis: an overview. In: Henderson B, Edwards JCW, Pettipher ER, editors. Mechanisms and models in rheumatoid arthritis. London: Academic Press, 1995: 363-71
9. Edwards JCW, Cambridge G. Is rheumatoid arthritis a failure of B cell death in synovium? Ann Rheum Dis 1995; 54: 696-700
10. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, et al. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-ex. J Immunol 1991; 146:3365-71
11. Morrissey PJ, Bressler L, Park LS, et al. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987; 139: 1113-9
12. Heidenreich S, Gong J-H, Schmidt A, et al. Macrophage activation by granulocyte/macrophage colony-stimulating factor: priming for enhanced release of tumor necrosis factor-a and prostaglandin E2. J Immunol 1989; 143: 1198-205
13. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992-9
14. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571 ) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42
15. Reiter C, van der Lubbe PA, Breedveld FC, et al. Chimeric monoclonal CD4 antibody CM-T412 induces a long lasting CD4 cell depletion in rheumatoid arthritis (RA) patients. Arthritis Rheum 1991; 34 Suppl.: S91
16. Moreland LW, Bucy RP, Tilden A, el al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36: 307-18
17. Elliott MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor ot (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
18. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993; 36: 1681-90
19. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7
20. Charles PJ, Elliott MJ, Feldmann M, et al. Development of ami dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha. Rheumatol Eur 1995; 24 Suppl. 3: 108
21. Rankin ECC, Ravirajan CT, Ehrenstein MR, et al. Serological effects following treatment with an engineered human antiTNFct antibody, CDP571, in patients with rheumatoid arthritis (RA). BrJ Rheumatol 1995; 34 Suppl. 1: 101
22. Lebsack ME, Paul CC, Martindale JJ, el al. A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36 Suppl.: S39
23. Drevlow B. Capezio J. Lovis R, et al. Phase I study of recombinant human interleukin-1 receptor (RHU IL-IR) administered intra-articularly in active rheumatoid arthritis. Arthritis Rheum 1993; 36 Suppl.; S39
24. van Leeuwen MA, Westra J, Limburg PC, et al. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial tluid. Ann Rheum Dis 1995; 54: 33-8
25. Arvidson NG. Gudbjornsson B, Elfman L, et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994:53: 521-4
26. Wendung D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993:20:259-62
27. Wendung D, Racadot E, Wijdenes J. Serum levels of 1L6. CRP, IL6 receptor and Cortisol under anti 1L6 monoclonal antibody therapy in rheumatoid arthritis. Arthritis Rheum 1994: 37 Suppl.: S382
28. Herzog C, Walker C. Pichler W. et al. Monoclonal anti-CD4 in arthritis [letter]. Lancet 1987; II: 146k-2
29. Herzog C. Walker C. Miller W, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J Autoimmun 1989; 2: 627-42
30. Choy EHS. Chikanza 1C, Kingsley GH, et al. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992; 36: 291-8
31. Moreland L. Pratt P, Mayes M, et al. Minimal efficacy of a depleting chimeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis receiving concomitant methotrexate (MTX). Arthritis Rheum 1993; 36 Suppl.: S39
32. van der Lubbe PA, Dijkmans BA. Markusse HM. et al. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1097-106
33. Strand V, Lipsky PE. Cannon GW, et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 1993; 36: 620-30
34. Kirkham BW. Pitzalis C, Kingsley GH, et al. Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991; 30: 459-63
35. Kirkham BW, Thien R Pelton BK, el al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992: 19: 1348-52
36. Kyle V, Coughlan RJ, Tighe H, et al. Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428-9
37. Isaacs JD, Watts RA, Hazleman BL. et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-52
38. Kavanaugh AF. Davis LS, Nichols LA. et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule I. Arthritis Rheum 1994: 37: 992-9
39. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1). Rheumatol Eur 1995: 24 Suppl. 2: 196-9
40. Montero-Julian FA, Klein B. Gautherot E, et al. Pharmacokinetic study of ami-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-lL-6 antibodies. Blood 1995; 85: 917-24
41. Williams RO. Mason LJ. Feldmann M, et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sei USA 1994:91: 2762-6